SCHEMBL3109971

SCHEMBL3109971

CC(Oc1ccc2nc(NC(=O)NCCCN(C)C)sc2c1)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.53
PIK3CG P48736 1/20 0.53
MET P08581 13/20 0.47
KDR P35968 6/20 0.46
LCK P06239 3/20 0.46
FGFR2 P21802 3/20 0.45
AXL P30530 3/20 0.45
FLT3 P36888 3/20 0.45
MST1R Q04912 3/20 0.45
SRC P12931 3/20 0.45
KIT P10721 2/20 0.45
ABL1 P00519 2/20 0.45
AURKA O14965 2/20 0.45
FYN P06241 2/20 0.45
EPHA2 P29317 2/20 0.45
LTK P29376 2/20 0.45
YES1 P07947 1/20 0.45
PTK6 Q13882 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102523 0.86 MET (0.46) METKDRLCKFGFR2AXL
SCHEMBL3098640 0.86 MET (0.46) METKDRLCKFGFR2AXL
SCHEMBL3102959 0.84 MET (0.51) METKDRLCKFGFR2AXL
SCHEMBL3102114 0.84 MET (0.51) METABL1NPC1RAB9AAURKB
SCHEMBL3104505 0.84 ABL1 (0.53) METKDRFGFR2AXLFLT3
SCHEMBL3114877 0.84 MET (0.50) METKDRLCKFGFR2AXL
SCHEMBL3655887 0.83 MET (0.54) METKDRLCKFGFR2AXL
SCHEMBL3788533 0.82 ABL1 (0.54) METKDRLCKFGFR2AXL
SCHEMBL3094120 0.82 MET (0.55) METABL1AURKB
SCHEMBL3097744 0.82 MET (0.55) METABL1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US claimed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US claimed
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2205568-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS Sanofi-Aventis (FR) 2010-07-14 EP disclosed
WO-2009087305-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS SANOFI-AVENTIS (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 PIK3CA 721/4885PIK3CG 1148/4885MET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.